Navigation Links
Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays.
Date:1/14/2010

CHICAGO, Jan. 14 /PRNewswire/ -- Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays.  The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers.  These increases in performance could aid researchers in basic and clinical science research, drug discovery, and clinical diagnostics development.

"We find the resolution at low concentrations to be an exciting benefit in our ovarian cancer and infertility research," said Professor Judith Luborsky, Ph.D., Associate Dean for Research, College of Health Sciences, Director, Laboratory for Ovarian Cancer Research and Director, Rush Proteomics & Biomarkers Core Research Facility at Rush University Medical Center.  "The technology was easily integrated into existing tests with minimal optimization and provided excellent improvements.  In fact, we have included Sword technology in several grants we are currently applying for."

"We are pleased with the positive reception our technology has received from the market. The key opinion leaders have found it particularly useful for highly sensitive ELISAs," said Dave Dingott, founder and CEO of Sword Diagnostics.  "The Raman plate reader allows current ELISA users to continue using their 96-well format, making conversion to our technology extremely simple and cost effective."

About Sword Diagnostics

Sword Diagnostic's mission is to improve existing immunoassays by providing additional sensitivity to currently available antibody-based test as well as allowing researchers to monitor new markers that are not readily detectable with current technology.  This may lead to earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer's disease.  Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.

Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays.  The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry.  The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.  

www.sworddiagnostics.com

SOURCE Sword Diagnostics Inc.

RELATED LINKS
http://www.sworddiagnostics.com

'/>"/>

SOURCE Sword Diagnostics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology
2. Inverness Medical Innovations Offers to Acquire Standard Diagnostics
3. Frost & Sullivan Recognizes IntelligentMDx for Its Commitment to the Advancement of Healthcare and Diagnostics
4. Fujirebio Diagnostics Named Life Sciences Company of the Year
5. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
6. Roche Diagnostics Opens State-of-the-Art Training Center in California
7. Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
8. Reportlinker Adds Molecular Diagnostics - A World Market Review
9. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
10. Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective
11. VIDA Diagnostics and Veran Medical Sign Definitive Agreement for Joint Development of Endobronchial Navigation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... March 28, 2017 The global ... USD 8.0 billion by 2025, according to a new ... of infectious diseases and cancer is expected to upsurge ... diagnosis over the coming years. In addition, higher number ... and allogenic stem cell therapy, due to adverse effects ...
(Date:3/27/2017)... Summary This report provides all the ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can now ... Sleep apnea is often left untreated because patients are not familiar with common symptoms ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, and ...
(Date:3/27/2017)... WI (PRWEB) , ... March 27, 2017 , ... ... new patients for custom smile makeovers without requiring a referral. Trimble ... orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients have discolored, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... Drs. Justin ... Awareness Week by teaching their patients about the key role this treatment plays in ... from an experienced endodontist. To better serve those who need a root canal in ...
(Date:3/27/2017)... Arlington, VA (PRWEB) , ... March 27, 2017 ... ... version 3.0 was transitioned to the OSEHRA popHealth Community in 2014. ... Steering Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member ...
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
Breaking Medicine News(10 mins):